SENS.L

Sensyne Health
Sensyne Health PLC - Rule 2.9 Announcement
21st March 2022, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3645F
Sensyne Health PLC
21 March 2022
 

      

 

Sensyne Health plc


("Sensyne" or the "Company")

 

Rule 2.9 Announcement

 

 

Oxford, U.K. - 21 March 2022: Sensyne Health plc (LSE:SENS) ("Sensyne" or the "Company") announces, for the purposes of Rule 2.9 of the City Code on Takeovers and Mergers, that, following the admission of 1,428,571 New Ordinary Shares today, it will have in issue 166,227,710 ordinary shares of ten pence nominal value each.

 

The International Securities Identification Number ("ISIN") code for the shares is GB00BYV3J755.

 

-ENDS-

 

Notes for editors:

About Sensyne Health: https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems.  The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

 

 

Contact details:

Sensyne Health

 

 

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Dr Richard Pye, Chief Financial Officer

+44 (0) 330 058 1845

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

 

Dr Christopher Golden

James Steel

 

 

 

Liberum (Joint Broker)

 

Phil Walker

William Hall

+ 44 (0) 20 3100 2000

Consilium Strategic Communications

 

Mary-Jane Elliott

Jessica Hodgson

CSCSensynehealth@consilium-comms.com

+44 (0) 7780 600290

SternIR

 

Julie Seidel

Julie.seidel@sternir.com

 +1 (212) 362 1200
       

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTEAEDEAFLAEAA ]]>
TwitterFacebookLinkedIn